Jakob Jobst

T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis

R. Flavell, M. Soengas, H. Anders, 2023, Immunity.

Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function

S. Endres, U. Schindler, S. Kobold, 2022, British Journal of Cancer.

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma

M. Heppt, C. Marr, S. Endres, 2023, Journal for ImmunoTherapy of Cancer.